Palatin Reports Second Quarter Fiscal Year 2024 Financial Re

Palatin's Focus is Solely on the Development of its Melanocortin Receptor (MCR) System Pipeline PL9643 MELODY-1 Pivotal Phase 3 Study in Dry Eye Disease (DED)...

Related Keywords

United States , American , Carl Spana , Palatin Technologies Inc , Cosette Pharmaceuticals , Prnewswire Palatin Technologies Inc , Vyleesi To Cosette Pharmaceuticals , Metabolic Program Obesity , Asset Sale To Cosette Pharmaceuticals , Sexual Health Program Male Dysfunction , Bremelanotide Co , Securities Exchange , Melanocortin Receptor , Dry Eye Disease , Topline Data Expected , Ulcerative Colitis , Interim Analysis Expected , Calendar Year , Topline Results Expected , Study Targeted , Sexual Dysfunction , Bremelanotide Co Formulated , Asset Sale , Gross Proceeds , Second Quarter Ended December , Health Program , Female Sexual Dysfunction , Direct Offering , Common Warrants , Registered Direct Offering , Eastern Time , Melanocortin Receptor Agonists , Palatin Technologies , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Months Ended December , Nc ,